Ilumya

Adults w/ moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

SC 100 mg at wk 0, 4, & every 12 wk thereafter.

Previous serious hypersensitivity.

Angioedema & urticaria. Discontinue treatment if serious hypersensitivity reaction occurs. Not to be initiated in patients w/ any clinically important active infection until infection resolves or adequately treated. Not to be administered in patients w/ active TB infection. Not to inj into areas where skin is affected by plaque psoriasis or is tender, bruised, red, hard, thick, or scaly; scars, stretch marks, or blood vessels. Consider discontinuation & closely monitor patient who develop clinically important or serious infection. Increased risk of infection. Evaluate patients for TB infection prior to initiating treatment. Consider anti-TB therapy prior to treatment initiation in patients w/ past history of latent or active TB in whom an adequate course of treatment cannot be confirmed; completion of all age appropriate immunizations prior to treatment initiation. Monitor patients for signs & symptoms of active TB during & after treatment. Patients w/ chronic infection or history of recurrent infection. Avoid use of live vaccines. Pregnancy & lactation.

Upper resp infections including nasopharyngitis, URTI, viral URTI & pharyngitis; inj site reactions including urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma & hemorrhage; diarrhea.

Avoid use of live vaccines.

Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

L04AC17 - tildrakizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

D